Remission in Global Airway Diseases: EUFOREA Consensus Paper
Year: 2026
Type: article
Abstract: The therapeutic goal in chronic airway diseases is shifting from symptom control to disease remission. Disease-modifying therapies, including biologics and allergen immunotherapy, have made remission achievable in patients with severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), or allergic rhinitis (AR). This EUFOREA consensus aims to establish practical guidance for inducing and maintaining remission in global airway diseases. An international panel of experts in pneumology, rhinology, and allergology convened in Rome (October 2025) to review current evidence and develop consensus statements. The panel achieved consensus on key principles: (i) remission is a therapeutic target independent of disease severity prior to treatment initiation and should not be reserved for severe cases; (ii) CRSwNP with nonallergic eosinophilic asthma, and AR with allergic asthma should be considered features of a single disease rather than comorbidities; (iii) remission should be assessed by each subspecialty separately while warranting combined approaches; (iv) pragmatic definitions prioritizing achievability and clinical utility are recommended; and (v) a 4-week recall window is preferred to assess symptom control within the evaluation of remission and a 12-month period is suggested as the minimal period to define remission. Remission represents an ambitious yet achievable goal, with practical guidance for optimizing patient outcomes.
Source: Allergy
DOI: 10.1111/all.70415
Authors: J. Christian Virchow, Xander Bertels, Vibeke Backer, Benjamin S. Bleier, Marco Caminati, Diego M. Conti, Eugenio De Corso, Mina Gaga, Valerie J. Lund, Corrado Pelaia, Anju T. Peters, Glenis K. Scadding, Martin Wagenmann, Riyad O. Al‐Lehebi, Guy G. Brusselle, Philippe Gevaert, Liam G. Heaney, Stella E. Lee, Florence Schleich, Frederik Trinkmann, Peter W. Hellings, Wytske J. Fokkens, Paola Rogliani
Institutions: Universitätsmedizin Rostock, University of Rostock, Ghent University, University of Copenhagen, Copenhagen University Hospital, Rigshospitalet, Massachusetts Eye and Ear Infirmary, Harvard University, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Universidad Autónoma de Madrid, KU Leuven, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Hygeia Hospital, University College London Hospitals NHS Foundation Trust, Eastman Dental Hospital, University College London, Magna Graecia University, Northwestern University, Düsseldorf University Hospital, Alfaisal University, King Fahd Medical City, Ghent University Hospital, Erasmus MC, Queen's University Belfast, Massachusetts General Hospital, Mass General Brigham, University of Liège, Centre Hospitalier Universitaire de Liège, Heidelberg University, German Center for Lung Research, University Medical Centre Mannheim, Universitair Ziekenhuis Leuven, Amsterdam University Medical Centers, University of Amsterdam, University of Rome Tor Vergata
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,300
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Teva Pharmaceutical Industries, Chiesi Farmaceutici, CSL Behring, Regeneron Pharmaceuticals, Celltrion, Insmed, Menarini Group, Genentech, Novartis Pharmaceuticals UK Limited, Allergopharma, Cilag
OpenAlex ID: W7165060110